Pharmacokinetics of 6-hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 7, 2007, Pages 393-402

  Dockens, Randy C ^a   Tran, Anh Q ^b   Zeng, Jianing ^a   Croop, Robert ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

1 PP; 6 hydroxybuspirone; Anxiety; Buspirone; Enantiomers; Pharmacokinetics

Indexed keywords

1 (2 PYRIMIDINYL)PIPERAZINE; 6 HYDROXY 8 [4 [4 [2 PYRIMIDINYL] 1 PIPERAZINYL]BUTYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; BMS 442606; BMS 442608; BMS 528215; BUSPIRONE; DRUG METABOLITE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG STRUCTURE; DRUG TOLERABILITY; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; AREA UNDER CURVE; BUSPIRONE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; STEREOISOMERISM;

EID: 35649008888     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.566     Document Type: Article

References (40)

1. Bristol-Myers Squibb Company. BuSpar (buspirone HCI) tablets. Physicians' Desk Reference (53rd edn). Thomson PDR: Montvale, NJ, 1999; 823-825.
2. Gorman JM. Treating generalized anxiety disorder. J Clin Psychiatry 2003; 64(Suppl. 2): 24-29.
3. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990; 10: 67S-76S.
4. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003; 53: 193-203.
5. Marangell LB. Augmentation of standard depression therapy. Clin Ther 2000; 22(Suppl. A): A25-A38; discussion A39-A41.
6. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selected serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448-452.
7. Rothschild AJ. New direction in the treatment of antidepressant-induced sexual dysfunction, Clin Ther 2000; 22(Suppl. A): A42-A47; discussion A58-A61.
8. Gitlin M. Sexual dysfunction with psychotropic drugs. Expert Opin Pharmacother 2003; 4: 2259-2269.
9. Niederhofer H. An open trial of buspirone in the treatment of attention-deficit disorder. Hum Psychopharmacol 2003; 18: 489-492.
10. Rynn M, Garcia-Espana F, Greenblatt DJ, Mandos LA, Schjweizer E, Rickels K. Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy. J Clin Psychopharmacol 2003; 23: 505-508.
11. Cooper JP. Buspirone for anxiety and agitation in dementia. J Psychiatry Neurosci 2003; 28: 469.
12. Cornelius JR, Bukstein O, Salloum I, Clark D. Alcohol and psychiatric comorbidity. Recent Dev Alcohol 2003; 16: 361-374.
13. 14C-buspirone HCl after intravenous and oral dosing in man. Clin Pharmacol Ther 1985; 37: 210.
14. Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med 1986; 80(Suppl. 3B): 41-51.
15. Gammans RE, Johnston RE. Metabolism, pharmacokinetics and toxicology of buspirone. In Buspirone: Mechanisms and Clinical Aspects, Tunnicliff G, Eison A, Taylor D (eds). Academic Press: San Diego, 1995; 223-260.
16. Caccia S, Conti J, Vigano G, Garattini S. 1-(2-pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology 1986; 33: 46-51.
17. Zhu M, Zhao W, Jimenez H et al. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 2005; 33: 500-507.
18. 1A partial agonist. Drug Metabolism and Disposition. DOI: 10.1124/dmd.107.015768
19. Dockens RC, Salazar DE, Fulmor IE, Croop R. Pharmacokinetics of a newly identified metabolite of buspirone following administration of buspirone over its therapeutic dose range. J Clin Pharmacol 2006; 46: 1308-1312.
20. Handley SL, McBlane JW, Critchley MAE, Njung'e K. Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behav Brain Res 1993; 58: 203-210.
21. 1A receptors. J Pharmacol Exp Ther 1993, 264: 863-872.
22. 1A receptor agonist. Fundam Clin Pharmacol 1993; 7: 413-427.
23. Matsuda T, Yoshikawa T, Suzuki M et al. Novel benzodioxan derivative, 5-(3-[((2S)-1,4-benzodioxan-2-yl-methyl)amino]propoxy)-1,3-benzodioxole HCI (MCK-242), with a highly potent and selective agonist activity at rat central serotonin 1A receptors. Jpn J Pharmacol 1995; 69: 357-366.
24. Cutler NR, Sramek JJ, Kurtz NM. Anxiolytic Compounds. Perspectives in Drug Development. Wiley: Chichester, 1996.
25. 2-adrenoceptors in the rat brain. Eur J Pharmacol 1983; 180: 183-186.
26. 2-Adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat. Eur J Pharmacol 1988; 155: 129-137.
27. Amano M, Goto A, Sakai A et al. Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats. Jpn J Pharmacol 1993; 61: 311-317.
28. De Vry J, Benz U, Schreiber R, Traber J. Shocked-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol 1993; 249: 331-339.
29. Cullen WK, Rowan MJ. Gepirone and 1-(2-pyrimidinyl)-piperazine-induced reduction of aversively evoked ultrasonic vocalisation in the rat. Pharmacol Biochem Behav 1994; 48: 301-306.
30. Cao BJ, Rodgers RJ. Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. Neuropharmacology 1997; 36: 1089-1097.
31. Gibaldi M, Perrier D. Pharmacokinetics (2nd edn). Marcel-Dekker. New York, NY, 1982; 409-417.
32. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980; 8:509-534.
33. Statistical Analysis System (SAS). Version 6.12. Cary (NC): SAS Institute, Inc; 1997.
34. Foster RT, Jamali F, Russell AS, Alballa SR. Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses. J Pharm Sci 1988; 77: 70-73.
35. Brocks DR, Jamali F, Russell AS, Skeith KJ. The stereoselective pharmacokinetics of etodolac in young and elderly subjects, and after cholecystectomy. J Clin Pharmacol 1992; 32: 982-989.
36. Oliary J, Tod M, Nicolas P, Petitjean O, Caille G. Pharmacokinetics of ibuprofen enantiomers after single and repeated doses in man. Biopharm Drug Dispos 1992; 13: 337-344.
37. Patel BK, Jackson SH, Swift CG, Hutt AJ. Disposition of flurbiprofen in man: influence of stereochemistry and age. Xenobiolica 2003; 33: 1043-1057.
38. Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 2007; 29: 223-227.
39. Rippley RK, Yan KX, Matthews ND, Greenberg HE, Herman GA, Wagner JA. Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARα/γ agonist. J Clin Pharmacol 2007; 47: 323-333.
40. Brocks DR. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharm drug Dispos 2006; 27: 387-406.